ReviewCells2022
Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study.PLoS computational biology · 2026Article
- Women with spondyloarthritis occurring in the peripartum period develop a singular phenotype.BMC musculoskeletal disorders · 2026Observational
- Human peripheral osteoclast-precursor-development patterns reveal the significance of RPS17-dependent ribosome synthesis to Ankylosing Spondylitis lesions.Bone research · 2025Article
- Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis.International journal of molecular sciences · 2025Article
- Arginase-1 and Mer Tyrosine Kinase Expression in Monocyte Populations in Patients with Axial Spondyloarthritis.Bulletin of experimental biology and medicine · 2025Article
- Compositional variation in eye-infiltrating immune cells distinguishes human uveitis subtypes.iScience · 2025Article
- Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges.Frontiers in immunology · 2025Review
- Monoclonal Antibodies Against Vascular Endothelial Growth Factor A (VEGF-A) Reduce Synovitis, Bone Damage, and Osteogenesis in an SKG Mouse Model of Spondyloarthritis.Journal of immunology research · 2025Article
- JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology.Frontiers in immunology · 2025Review
- An Actual Insight into the Pathogenic Pathways of Ankylosing Spondylitis.Current issues in molecular biology · 2024Review
- Increased carotid intima-media thickness in patients with radiographic axial spondyloarthritis compared to controls and associations with markers of inflammation.Clinical rheumatology · 2024Article
- Increased Circulating CD14+ Monocytes in Patients with Psoriatic Arthritis Presenting Impaired Apoptosis Activity.Biomedicines · 2024Article
- Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors.Journal of clinical medicine · 2024Article
- Regulation mechanisms of disulfidptosis-related genes in ankylosing spondylitis and inflammatory bowel disease.Frontiers in immunology · 2024Article
- Dissecting CYP1A2 Activation by Arylalkanoic Acid Prodrugs toward the Development of Anti-Inflammatory Agents.International journal of molecular sciences · 2023Article
- The Usefulness of Cellular Immune Inflammation Markers and Ultrasound Evaluation in the Assessment of Disease Activity in Patients with Spondyloarthritis.Journal of clinical medicine · 2023Article
- Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.International journal of molecular sciences · 2023Observational
- Thrombocytosis in patients with spondyloarthritis: a case-control study.BMC musculoskeletal disorders · 2023Article
- High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Exploration of the shared pathways and common biomarker PAN3 in ankylosing spondylitis and ulcerative colitis using integrated bioinformatics analysis.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spondyloarthritis (SpA) is a family of chronic inflammatory diseases, being the most prevalent ankylosing spondylitis (AS) and psoriatic arthritis (PsA). These diseases share genetic, clinical and immunological features, such as the implication of human leukocyte antigen (HLA) class I molecule 27 (HLA-B27), the inflammation of peripheral, spine and sacroiliac joints and the presence of extra-articular manifestations (psoriasis, anterior uveitis, enthesitis and inflammatory bowel disease). Monocytes and macrophages are essential cells of the innate immune system and are the first line of defence against external agents. In rheumatic diseases including SpA, the frequency and phenotypic and functional characteristics of both cell types are deregulated and are involved in the pathogenesis of these diseases. In fact, monocytes and macrophages play key roles in the inflammatory processes characteristics of SpA. The aim of this review is analysing the characteristics and functional roles of monocytes and macrophages in these diseases, as well as the impact of different current therapies on these cell types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.